Sponsored by:
Antibody Engineering and Therapeutics Asia
THE ONLY EVENT IN ASIA PROVIDING THE LATEST SCIENCE, TECHNOLOGY AND PARTNERS TO ACCELERATE ANTIBODY & PROTEIN THERAPIES, ADCS, BISPECIFICS AND IMMUNO-ONCOLOGY
World-renowned scientists sharing the latest technologies, R&D and clinical data to fast-track your next-generation therapeutics towards commercial success
NEW TECHNOLOGIES, R&D ADVANCES AND CLINICAL DATA TO HELP YOU FAST-TRACK NEXT-GENERATION THERAPEUTICS TO MARKET
Novel Approaches to Accelerate Therapeutic Development
- Sally Ward’s Research on Targeting Intracellular Trafficking Pathways for the Design of Therapeutics
- Shohei Koide’s Advances in Novel Therapeutics Based on Synthetic Binding Proteins
- Lava Therapeutics’ Novel Bispecific γδ-T cell Engagers for the Treatment of Cancer
- Chugai’s Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors
- Takeda’s Vision for Antibody Drug Discovery: An Overview of Programs and Progress
- Koji Tamada’s Prime CAR Technology, a Novel Platform of T cell Therapy Against Solid Tumors
Scientific Case Studies and New Data
- Invenra, Amgen, Argenx, Xencor, Immatics and AbbVie Case Studies and New Data
- Eisai’s Progress on the Development of a Novel Anti-Tau Antibody
- NBE-Therapeutics’ Update on NBE-002, An Anthracycline-based Immune-stimulatory Antibody Drug Conjugate
- Sai Reddy’s Data on How Deep Learning Enables Therapeutic Antibody Optimization in Mammalian Cells
- Genentech’s MerTK Blockade Which Enhances Antitumor Immunity
- Dainippon Sumitomo’s Antibody Intracellular Activated Drug Conjugate (AiADC) As a Novel ADC Technology
New This Year!
- Workshop on Engineering Strategies for TCR and CAR T Cell Therapies
- World-Renowned Academic and Industry Keynotes
- More Confirmed Speakers from Leading US and European Antibody Companies
- More Science and Data - 80% of Speakers Are New This Year
- Kyoto, Japan Location – Voted in Many Surveys As One of the Top Cities in the World to Visit
- Expanded Exhibit and Poster Sessions
GET EVEN MORE BY ATTENDING THIS GROUNDBREAKING WORKSHOP
ENGINEERING STRATEGIES FOR TCR AND CAR T CELL THERAPIES
24 February - 9:00 am - 12:45 pm
- Prime CAR Technology, a Novel Platform of T cell Therapy Against Solid Tumors
- Cellular Screening Platforms for Engineering T cell Receptors and Chimeric Antigen Receptors
- Effective Targeting of Tumor-specific pMHC Targets with Bispecific T cell-engaging Receptor (TCER®) Molecules
- Massively Parallel Interrogation and Mining of Nativelypaired Human TCRab Repertoires
